{
    "nctId": "NCT01187381",
    "briefTitle": "An Observational Study of the Mean Duration of Trastuzumab (Herceptin) Treatment in Participants With Early or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer",
    "officialTitle": "Multicenter, Single-Arm, Observational Study of Mean Duration of Trastuzumab (Herceptin) Treatment in Patients With HER2-Positive Early or Metastatic Breast Cancer in Romanian Population",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 250,
    "primaryOutcomeMeasure": "Treatment Duration With Trastuzumab in the Routine Clinical Practice",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* HER2-positive breast cancer\n* Treated with trastuzumab in accordance with Summary of Product Characteristics and local protocols\n* Written informed consent to data collection\n\nExclusion Criteria:\n\n* Any contraindication to trastuzumab\n* Clinically relevant cardiovascular disorder or disease",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}